Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

139 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Molecular classification of hormone receptor-positive HER2-negative breast cancer.
Jin X, Zhou YF, Ma D, Zhao S, Lin CJ, Xiao Y, Fu T, Liu CL, Chen YY, Xiao WX, Liu YQ, Chen QW, Yu Y, Shi LM, Shi JX, Huang W, Robertson JFR, Jiang YZ, Shao ZM. Jin X, et al. Among authors: robertson jfr. Nat Genet. 2023 Oct;55(10):1696-1708. doi: 10.1038/s41588-023-01507-7. Epub 2023 Sep 28. Nat Genet. 2023. PMID: 37770634
Clinico-pathologic relationships with Ki67 and its change with short-term aromatase inhibitor treatment in primary ER + breast cancer: further results from the POETIC trial (CRUK/07/015).
Bliss JM, Tovey H, Evans A, Holcombe C, Horgan K, Mallon E, Vidya R, Skene A, Dodson A, Hills M, Detre S, Zabaglo L, Banerji J, Kilburn L, Morden JP, Robertson JFR, Smith I, Dowsett M; POETIC Trialists. Bliss JM, et al. Among authors: robertson jfr. Breast Cancer Res. 2023 Apr 12;25(1):39. doi: 10.1186/s13058-023-01626-3. Breast Cancer Res. 2023. PMID: 37046348 Free PMC article. Clinical Trial.
Correction: Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER+ Invasive Breast Cancer (STAKT).
Robertson JFR, Coleman RE, Cheung KL, Evans A, Holcombe C, Skene A, Rea D, Ahmed S, Jahan A, Horgan K, Rauchhaus P, Littleford R, Amy Cheung SY, Cullberg M, de Bruin EC, Koulai L, Lindemann JPO, Pass M, Rugman P, Schiavon G, Deb R, Finlay P, Foxley A, Gee JMW. Robertson JFR, et al. Clin Cancer Res. 2022 Dec 15;28(24):5469. doi: 10.1158/1078-0432.CCR-22-3568. Clin Cancer Res. 2022. PMID: 36519303 No abstract available.
Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor-positive Breast Cancers.
Bergamino MA, Morani G, Parker J, Schuster EF, Leal MF, López-Knowles E, Tovey H, Bliss JM, Robertson JFR, Smith IE, Dowsett M, Cheang MCU. Bergamino MA, et al. Among authors: robertson jfr. Clin Cancer Res. 2022 Mar 15;28(6):1217-1228. doi: 10.1158/1078-0432.CCR-21-2718. Clin Cancer Res. 2022. PMID: 34965950 Free PMC article.
139 results